Market Access/ News/ News/ News/ R&D/ Top stories Allergan builds case for migraine drug ubrogepant as FDA verdict nears Phil Taylor Allergan, central nervous system, CGRP, migraine, ubrogepant 0 Comment Allergan’s ubrogepant could become the first oral drug in the new CGRP inhibitor class if it is approved Share X Allergan builds case for migraine drug ubrogepant as FDA verdict nears https://pharmaphorum.com/news/allergan-builds-case-for-migraine-drug-ubrogepant-as-fda-verdict-nears/